Form 8-K - Current report:
SEC Accession No. 0001193125-25-049988
Filing Date
2025-03-07
Accepted
2025-03-07 17:21:03
Documents
15
Period of Report
2025-03-07
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d811414d8k.htm   iXBRL 8-K 25573
2 EX-99.1 d811414dex991.htm EX-99.1 8448
6 GRAPHIC g811414dsp5.jpg GRAPHIC 3317
  Complete submission text file 0001193125-25-049988.txt   159960

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20250307.xsd EX-101.SCH 2498
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20250307_lab.xml EX-101.LAB 17202
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20250307_pre.xml EX-101.PRE 10780
18 EXTRACTED XBRL INSTANCE DOCUMENT d811414d8k_htm.xml XML 3616
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38624 | Film No.: 25721287
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)